HIF–prolyl hydroxylases and cardiovascular diseases

References

• Adluri RS, Thirunavukkarasu M, Dunna NR, Zhan L, Oriowo B, Takeda K, Sanchez JA, Otani H, Maulik G, Fong GH, Maulik N. 2011. Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1α transcription factor and its target genes in mice. Antioxid Redox Signal 15:1789–1797.
   PubMed Web of Science ®Google Scholar
• Ameln AK, Muschter A, Mamlouk S, Kalucka J, Prade I, Franke K, Rezaei M, Poitz DM, Breier G, Wielockx B. 2011. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFβ. Cancer Res 71:3306–3316.
   Google Scholar
• Aminova LR, Chavez JC, Lee J, Ryu H, Kung A, Lamanna JC, Ratan RR. 2005. Prosurvival and prodeath effects of hypoxia-inducible factor-1α stabilization in a murine hippocampal cell line. J Biol Chem 280:3996–4003.
   PubMed Web of Science ®Google Scholar
• Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM. 2004. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279:38458–38465.
   PubMed Web of Science ®Google Scholar
• Aragonés J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, Mazzone M, Dirkx R, Zacchigna S, Lemieux H, Jeoung NH, Lambrechts D, Bishop T, Lafuste P, Diez-Juan A, Harten SK, Van Noten P, De Bock K, Willam C, Tjwa M, Grosfeld A, Navet R, Moons L, Vandendriessche T, Deroose C, Wijeyekoon B, Nuyts J, Jordan B, Silasi-Mansat R, Lupu F, Dewerchin M, Pugh C, Salmon P, Mortelmans L, Gallez B, Gorus F, Buyse J, Sluse F, Harris RA, Gnaiger E, Hespel P, Van Hecke P, Schuit F, Van Veldhoven P, Ratcliffe P, Baes M, Maxwell P, Carmeliet P. 2008. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 40:170–180.
   PubMed Web of Science ®Google Scholar
• Asikainen TM, Ahmad A, Schneider BK, Ho WB, Arend M, Brenner M, Günzler V, White CW. 2005. Stimulation of HIF-1α, HIF-2α, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells. Free Radic Biol Med 38:1002–1013.
   PubMed Web of Science ®Google Scholar
• Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M, Chan DA, Giaccia AJ, Semenza GL. 2005. OS-9 interacts with hypoxia-inducible factor 1α and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1α. Mol Cell 17:503–512.
   PubMed Web of Science ®Google Scholar
• Bao W, Qin P, Needle S, Erickson-Miller CL, Duffy KJ, Ariazi JL, Zhao S, Olzinski AR, Behm DJ, Pipes GC, Jucker BM, Hu E, Lepore JJ, Willette RN. 2010. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol 56:147–155.
   PubMed Web of Science ®Google Scholar
• Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, Chavez JC. 2007. Neuron-specific inactivation of the hypoxia inducible factor 1 α increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci 27:6320–6332.
   PubMed Web of Science ®Google Scholar
• Barth S, Nesper J, Hasgall PA, Wirthner R, Nytko KJ, Edlich F, Katschinski DM, Stiehl DP, Wenger RH, Camenisch G. 2007. The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol Cell Biol 27:3758–3768.
   PubMed Web of Science ®Google Scholar
• Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P. 1994. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89:151–163.
   PubMed Web of Science ®Google Scholar
• Bernhardt WM, Câmpean V, Kany S, Jürgensen JS, Weidemann A, Warnecke C, Arend M, Klaus S, Günzler V, Amann K, Willam C, Wiesener MS, Eckardt KU. 2006. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol 17:1970–1978.
   PubMed Web of Science ®Google Scholar
• Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22:4082–4090.
   PubMed Web of Science ®Google Scholar
• Berra E, Ginouvès A, Pouysségur J. 2006. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep 7:41–45.
   PubMed Web of Science ®Google Scholar
• Berra E, Roux D, Richard DE, Pouysségur J. 2001. Hypoxia-inducible factor-1 α (HIF-1 α) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep 2:615–620.
   PubMed Web of Science ®Google Scholar
• Bruick RK. 2000. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 97:9082–9087.
   PubMed Web of Science ®Google Scholar
• Cerami A, Brines ML, Ghezzi P, Cerami CJ. 2001. Effects of epoetin alfa on the central nervous system. Semin Oncol 28:66–70.
   Google Scholar
• Cervera AM, Apostolova N, Luna-Crespo F, Sanjuan-Pla A, Garcia-Bou R, McCreath KJ. 2006. An alternatively spliced transcript of the PHD3 gene retains prolyl hydroxylase activity. Cancer Lett 233:131–138.
   Google Scholar
• Chan DA, Sutphin PD, Denko NC, Giaccia AJ. 2002. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α. J Biol Chem 277:40112–40117.
   PubMed Web of Science ®Google Scholar
• Chan DA, Sutphin PD, Yen SE, Giaccia AJ. 2005. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 α. Mol Cell Biol 25:6415–6426.
   PubMed Web of Science ®Google Scholar
• Chavez JC, Baranova O, Lin J, Pichiule P. 2006. The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci 26:9471–9481.
   PubMed Web of Science ®Google Scholar
• De Carvalho Frimm C, Sun Y, Weber KT. 1997. Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med 129:439–446.
   Google Scholar
• del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, Olmos G, Landazuri MO. 2003. The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem 278:48690–48695.
   PubMed Web of Science ®Google Scholar
• Eckle T, Köhler D, Lehmann R, El Kasmi K, Eltzschig HK. 2008. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118:166–175.
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL. 2002. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495–505.
   PubMed Web of Science ®Google Scholar
• Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43–54.
   PubMed Web of Science ®Google Scholar
• Fielitz J, Philipp S, Herda LR, Schuch E, Pilz B, Schubert C, Günzler V, Willenbrock R, Regitz-Zagrosek V. 2007. Inhibition of prolyl 4-hydroxylase prevents left ventricular remodelling in rats with thoracic aortic banding. Eur J Heart Fail 9:336–342.
   PubMed Web of Science ®Google Scholar
• Fraisl P, Aragonés J, Carmeliet P. 2009. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 8:139–152.
   PubMed Web of Science ®Google Scholar
• Francis GS, Mcdonald KM, Cohn JN 1993. Neurohumoral activation in preclinical heart failure. Remodeling and the potential for intervention. Circulation 87:IV90–96.
   Google Scholar
• Frazier DP, Wilson A, Graham RM, Thompson JW, Bishopric NH, Webster KA. 2006. Acidosis regulates the stability, hydrophobicity, and activity of the BH3-only protein Bnip3. Antioxid Redox Signal 8:1625–1634.
   PubMed Web of Science ®Google Scholar
• Frei C, Edgar BA. 2004. Drosophila cyclin D/Cdk4 requires Hif-1 prolyl hydroxylase to drive cell growth. Dev Cell 6:241–251.
   PubMedGoogle Scholar
• Frey N, Katus HA, Olson EN, Hill JA. 2004. Hypertrophy of the heart: a new therapeutic target? Circulation 109:1580–1589.
   PubMed Web of Science ®Google Scholar
• Frey N, Olson EN. 2003. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45–79.
   PubMed Web of Science ®Google Scholar
• Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouysségur J, Yaniv M, Mechta-Grigoriou F. 2004. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118:781–794.
   PubMed Web of Science ®Google Scholar
• Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT. 1998. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95:8795–8800.
   PubMed Web of Science ®Google Scholar
• Halestrap AP, Clarke SJ, Javadov SA. 2004. Mitochondrial permeability transition pore opening during myocardial reperfusion–a target for cardioprotection. Cardiovasc Res 61:372–385.
   PubMed Web of Science ®Google Scholar
• Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, Bauer EP, Klövekorn WP, Schaper J. 2003. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107:984–991.
   PubMed Web of Science ®Google Scholar
• Hewitson KS, McNeill LA, Schofield CJ. 2004. Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr Pharm Des 10:821–833.
   PubMedGoogle Scholar
• Hirota K, Semenza GL. 2006. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59:15–26.
   PubMed Web of Science ®Google Scholar
• Hirsilä M, Koivunen P, Günzler V, Kivirikko KI, Myllyharju J. 2003. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278:30772–30780.
   PubMed Web of Science ®Google Scholar
• Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, Hankinson O. 1991. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252:954–958.
   PubMed Web of Science ®Google Scholar
• Hopfer U, Hopfer H, Jablonski K, Stahl RA, Wolf G. 2006. The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3). J Biol Chem 281:8645–8655.
   Google Scholar
• Huang J, Zhao Q, Mooney SM, Lee FS. 2002. Sequence determinants in hypoxia-inducible factor-1α for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J Biol Chem 277:39792–39800.
   PubMed Web of Science ®Google Scholar
• Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. 1996. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271:17771–17778.
   PubMed Web of Science ®Google Scholar
• Jiang BH, Semenza GL, Bauer C, Marti HH. 1996. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271:C1172–C1180.
   PubMed Web of Science ®Google Scholar
• Judd JT, Wexler BC. 1975. Prolyl hydroxylase and collagen metabolism after experimental mycardial infarction. Am J Physiol 228:212–216.
   Google Scholar
• Katschinski DM. 2009. In vivo functions of the prolyl-4-hydroxylase domain oxygen sensors: direct route to the treatment of anaemia and the protection of ischaemic tissues. Acta Physiol (Oxf) 195:407–414.
   PubMed Web of Science ®Google Scholar
• Ke Q, Costa M. 2006. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70:1469–1480.
   PubMed Web of Science ®Google Scholar
• Kevin LG, Camara AK, Riess ML, Novalija E, Stowe DF. 2003. Ischemic preconditioning alters real-time measure of O2 radicals in intact hearts with ischemia and reperfusion. Am J Physiol Heart Circ Physiol 284:H566–H574.
   PubMed Web of Science ®Google Scholar
• Kubasiak LA, Hernandez OM, Bishopric NH, Webster KA. 2002. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci USA 99:12825–12830.
   PubMed Web of Science ®Google Scholar
• Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG Jr, Schlisio S. 2005. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8:155–167.
   PubMed Web of Science ®Google Scholar
• Levraut J, Iwase H, Shao ZH, Vanden Hoek TL, Schumacker PT. 2003. Cell death during ischemia: relationship to mitochondrial depolarization and ROS generation. Am J Physiol Heart Circ Physiol 284:H549–H558.
   PubMed Web of Science ®Google Scholar
• Liu J, Narasimhan P, Yu F, Chan PH. 2005. Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin. Stroke 36:1264–1269.
   PubMed Web of Science ®Google Scholar
• Liu R, Suzuki A, Guo Z, Mizuno Y, Urabe T. 2006. Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro. J Neurochem 96:1101–1110.
   PubMed Web of Science ®Google Scholar
• Loinard C, Ginouvès A, Vilar J, Cochain C, Zouggari Y, Recalde A, Duriez M, Lévy BI, Pouysségur J, Berra E, Silvestre JS. 2009. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. Circulation 120:50–59.
   PubMed Web of Science ®Google Scholar
• Lomb DJ, Straub JA, Freeman RS. 2007. Prolyl hydroxylase inhibitors delay neuronal cell death caused by trophic factor deprivation. J Neurochem 103:1897–1906.
   PubMedGoogle Scholar
• Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators. 2001. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104:1615–1621.
   PubMed Web of Science ®Google Scholar
• McDonough MA, Li V, Flashman E, Chowdhury R, Mohr C, Liénard BM, Zondlo J, Oldham NJ, Clifton IJ, Lewis J, McNeill LA, Kurzeja RJ, Hewitson KS, Yang E, Jordan S, Syed RS, Schofield CJ. 2006. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci USA 103:9814–9819.
   PubMed Web of Science ®Google Scholar
• Menzies K, Liu B, Kim WJ, Moschella MC, Taubman MB. 2004. Regulation of the SM-20 prolyl hydroxylase gene in smooth muscle cells. Biochem Biophys Res Commun 317:801–810.
   PubMedGoogle Scholar
• Metzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M, Huang WQ, Wotzlaw C, Hellwig-Bürgel T, Jelkmann W, Acker H, Fandrey J. 2003. Intracellular localisation of human HIF-1 α hydroxylases: implications for oxygen sensing. J Cell Sci 116:1319–1326.
   PubMed Web of Science ®Google Scholar
• Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG Jr. 2008. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111:3236–3244.
   PubMed Web of Science ®Google Scholar
• Moschella MC, Menzies K, Tsao L, Lieb MA, Kohtz JD, Kohtz DS, Taubman MB. 1999. SM-20 is a novel growth factor-responsive gene regulated during skeletal muscle development and differentiation. Gene Expr 8:59–66.
   Google Scholar
• Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG Jr. 2010. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation 122:1004–1016.
   PubMed Web of Science ®Google Scholar
• Muchnik E, Kaplan J. 2011. HIF prolyl hydroxylase inhibitors for anemia. Expert Opin Investig Drugs 20:645–656.
   PubMed Web of Science ®Google Scholar
• Mussini E, Hutton JJ Jr, Udenfriend S. 1967. Collagen proline hydroxylase in wound healing, granuloma formation, scurvy, and growth. Science 157:927–929.
   PubMed Web of Science ®Google Scholar
• Ng KM, Lee YK, Chan YC, Lai WH, Fung ML, Li RA, Siu CW, Tse HF. 2010. Exogenous expression of HIF-1 α promotes cardiac differentiation of embryonic stem cells. J Mol Cell Cardiol 48:1129–1137.
   PubMed Web of Science ®Google Scholar
• Nigra TP, Friedland M, Martin GR. 1972. Controls of connective tissue synthesis: collagen metabolism. J Invest Dermatol 59:44–49.
   PubMed Web of Science ®Google Scholar
• Nwogu JI, Geenen D, Bean M, Brenner MC, Huang X, Buttrick PM. 2001. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104:2216–2221.
   Google Scholar
• Ockaili R, Natarajan R, Salloum F, Fisher BJ, Jones D, Fowler AA 3rd, Kukreja RC. 2005. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol 289:H542–H548.
   PubMed Web of Science ®Google Scholar
• Oehme F, Ellinghaus P, Kolkhof P, Smith TJ, Ramakrishnan S, Hütter J, Schramm M, Flamme I. 2002. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem Biophys Res Commun 296:343–349.
   PubMed Web of Science ®Google Scholar
• Peterkofsky B, Udenfriend S. 1963. Conversion of proline to collagen hydroxyproline in a cell-free system from chick embryo. J Biol Chem 238:3966–3977.
   PubMed Web of Science ®Google Scholar
• Prass K, Scharff A, Ruscher K, Löwl D, Muselmann C, Victorov I, Kapinya K, Dirnagl U, Meisel A. 2003. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34:1981–1986.
   PubMed Web of Science ®Google Scholar
• Ratan RR, Siddiq A, Smirnova N, Karpisheva K, Haskew-Layton R, McConoughey S, Langley B, Estevez A, Huerta PT, Volpe B, Roy S, Sen CK, Gazaryan I, Cho S, Fink M, LaManna J. 2007. Harnessing hypoxic adaptation to prevent, treat, and repair stroke. J Mol Med 85:1331–1338.
   PubMedGoogle Scholar
• Reisz-Porszasz S, Probst MR, Fukunaga BN, Hankinson O. 1994. Identification of functional domains of the aryl hydrocarbon receptor nuclear translocator protein (ARNT). Mol Cell Biol 14:6075–6086.
   PubMed Web of Science ®Google Scholar
• Samuel SM, Thirunavukkarasu M, Penumathsa SV, Paul D, Maulik N. 2008. Akt/FOXO3a/SIRT1-mediated cardioprotection by n-tyrosol against ischemic stress in rat in vivo model of myocardial infarction: switching gears toward survival and longevity. J Agric Food Chem 56:9692–9698.
   Google Scholar
• Sasaki H, Zhu L, Fukuda S, Maulik N. 2000. Inhibition of NF κ B activation by pyrrolidine dithiocarbamate prevents in vivo hypoxia/reoxygenation-mediated myocardial angiogenesis. Int J Tissue React 22:93–100.
   PubMedGoogle Scholar
• Schaper J, Speiser B. 1992. The extracellular matrix in the failing human heart. Basic Res Cardiol 87 Suppl 1:303–309.
   PubMed Web of Science ®Google Scholar
• Schneider M, Van Geyte K, Fraisl P, Kiss J, Aragonés J, Mazzone M, Mairbäurl H, De Bock K, Jeoung NH, Mollenhauer M, Georgiadou M, Bishop T, Roncal C, Sutherland A, Jordan B, Gallez B, Weitz J, Harris RA, Maxwell P, Baes M, Ratcliffe P, Carmeliet P. 2010. Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. Gastroenterology 138:1143–54.e1.
   PubMed Web of Science ®Google Scholar
• Schofield CJ, Ratcliffe PJ. 2004. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5:343–354.
   PubMed Web of Science ®Google Scholar
• Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7:77–85.
   PubMed Web of Science ®Google Scholar
• Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, Leung S, Roe R, Wiener C, Yu A. 1997. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 51:553–555.
   PubMed Web of Science ®Google Scholar
• Shingo T, Sorokan ST, Shimazaki T, Weiss S. 2001. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 21:9733–9743.
   PubMed Web of Science ®Google Scholar
• Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, Lamanna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, Ratan RR. 2005. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280:41732–41743.
   PubMedGoogle Scholar
• Silverman HS, Stern MD. 1994. Ionic basis of ischaemic cardiac injury: insights from cellular studies. Cardiovasc Res 28:581–597.
   PubMed Web of Science ®Google Scholar
• Solaini G, Harris DA. 2005. Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion. Biochem J 390:377–394.
   PubMed Web of Science ®Google Scholar
• Straub JA, Lipscomb EA, Yoshida ES, Freeman RS. 2003. Induction of SM-20 in PC12 cells leads to increased cytochrome c levels, accumulation of cytochrome c in the cytosol, and caspase-dependent cell death. J Neurochem 85:318–328.
   Google Scholar
• Takeda K, Fong GH. 2007. Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation. Hypertension 49:178–184.
   PubMed Web of Science ®Google Scholar
• Tekin D, Dursun AD, Xi L. 2010. Hypoxia inducible factor 1 (HIF-1) and cardioprotection. Acta Pharmacol Sin 31:1085–1094.
   PubMed Web of Science ®Google Scholar
• Temes E, Martín-Puig S, Acosta-Iborra B, Castellanos MC, Feijoo-Cuaresma M, Olmos G, Aragonés J, Landazuri MO. 2005. Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. J Biol Chem 280:24238–24244.
   PubMed Web of Science ®Google Scholar
• Tian YM, Mole DR, Ratcliffe PJ, Gleadle JM. 2006. Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation. Biochem J 397:179–186.
   PubMed Web of Science ®Google Scholar
• Tsai MS, Hwang SM, Tsai YL, Cheng FC, Lee JL, Chang YJ. 2006. Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod 74:545–551.
   PubMed Web of Science ®Google Scholar
• Tuckerman JR, Zhao Y, Hewitson KS, Tian YM, Pugh CW, Ratcliffe PJ, Mole DR. 2004. Determination and comparison of specific activity of the HIF-prolyl hydroxylases. FEBS Lett 576:145–150.
   Google Scholar
• Udenfriend S. 1966. Formation of hydroxyproline in collagen. Science 152:1335–1340.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, Solinas P, Gorini M, Maggioni AP; MAVI (MAssa Ventricolare sinistra nell’Ipertensione) Study Group. 2001. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 38:1829–1835.
   PubMed Web of Science ®Google Scholar
• Vincent KA, Feron O, Kelly RA. 2002. Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc Med 12:362–367.
   PubMed Web of Science ®Google Scholar
• Wang GL, Semenza GL. 1995. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230–1237.
   PubMed Web of Science ®Google Scholar
• Wang GL, Jiang B-H, Rue EA, Semenza GL 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular 02 tension. Proc NatlAcad Sci USA 90:4304.
   Google Scholar
• Warnecke C, Griethe W, Weidemann A, Jürgensen JS, Willam C, Bachmann S, Ivashchenko Y, Wagner I, Frei U, Wiesener M, Eckardt KU. 2003. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 17:1186–1188.
   PubMed Web of Science ®Google Scholar
• Wax SD, Rosenfield CL, Taubman MB. 1994. Identification of a novel growth factor-responsive gene in vascular smooth muscle cells. J Biol Chem 269:13041–13047.
   PubMedGoogle Scholar
• Wax SD, Tsao L, Lieb ME, Fallon JT, Taubman MB. 1996. SM-20 is a novel 40-kd protein whose expression in the arterial wall is restricted to smooth muscle. Lab Invest 74:797–808.
   Google Scholar
• Weber KT, Sun Y, Katwa LC, Cleutjens JP. 1995. Connective tissue: a metabolic entity? J Mol Cell Cardiol 27:107–120.
   Google Scholar
• Wei L, Han BH, Li Y, Keogh CL, Holtzman DM, Yu SP. 2006. Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats. J Pharmacol Exp Ther 317:109–116.
   PubMed Web of Science ®Google Scholar
• Wiener CM, Booth G, Semenza GL. 1996. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 225:485–488.
   PubMed Web of Science ®Google Scholar
• Wu S, Nishiyama N, Kano MR, Morishita Y, Miyazono K, Itaka K, Chung UI, Kataoka K. 2008. Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. Mol Ther 16:1227–1234.
   Google Scholar
• Yeo EJ, Cho YS, Kim MS, Park JW. 2008. Contribution of HIF-1α or HIF-2α to erythropoietin expression: in vivo evidence based on chromatin immunoprecipitation. Ann Hematol 87:11–17.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Hilliard G, Ferguson T, Millhorn DE. 2003. Cobalt inhibits the interaction between hypoxia-inducible factor-α and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-α. J Biol Chem 278:15911–15916.
   PubMed Web of Science ®Google Scholar
• Zweier JL, Flaherty JT, Weisfeldt ML. 1987. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci USA 84:1404–1407.
   PubMed Web of Science ®Google Scholar